Overview: an iPS cell stock at CiRA
Induced pluripotent stem cells (iPSCs) can be produced from various somatic cells and have the ability to differentiate into various cells and tissues of the body. Regenerative medicine using iPSCs is expected to manage diseases lacking effective treatments at present. We are establishing a safe and...
Gespeichert in:
| Veröffentlicht in: | Inflammation and Regeneration 2019-09, Vol.39 (1), p.17-17, Article 17 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17 |
|---|---|
| container_issue | 1 |
| container_start_page | 17 |
| container_title | Inflammation and Regeneration |
| container_volume | 39 |
| creator | Umekage, Masafumi Sato, Yoshiko Takasu, Naoko |
| description | Induced pluripotent stem cells (iPSCs) can be produced from various somatic cells and have the ability to differentiate into various cells and tissues of the body. Regenerative medicine using iPSCs is expected to manage diseases lacking effective treatments at present. We are establishing a safe and effective iPSC stock that can be used for regenerative medicine. Our iPSC stock is recruited from healthy, consenting HLA-type homozygous donors and is made with peripheral blood-derived mononuclear cells or umbilical cord blood. We hope to minimize the influence of immune rejection by preparing HLA homozygous iPSCs. Our stock is made at the Cell Processing Center (CPC), Center for iPS Cell Research and Application (CiRA). We are preparing iPS cells that maximize matching of the Japanese population at the major HLA loci. This iPSC stock is intended to be offered not only to Japanese centers but also overseas medical institutions and companies. In August 2015, we began offering the iPSC stock for regenerative medicine and now offer 21 clones made from 5 donors. |
| doi_str_mv | 10.1186/s41232-019-0106-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6717959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A600209472</galeid><doaj_id>oai_doaj_org_article_7596192b338546af8f1b23e52b7daf68</doaj_id><sourcerecordid>A600209472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c556t-531b5064da6b4efec220863ad570e81ca88862ad7af4b0ba866f5a8a5a54c9773</originalsourceid><addsrcrecordid>eNpdUl1rFDEUHcRiS9sf4IsM9MWXqbnJ5MsHYVm0FgotVZ_DnUyyZp2d1GR2xX_frLMWa0JIuDnn5ObeU1WvgVwCKPEut0AZbQjosohoyIvqBJQijQJNXh7OWmh2XJ3nvCZlcME56FfVMYNWS1DkpLq43bm0C-7X-xrHOtx9qa0bhjpP0f6ocaqX4X5xVh15HLI7P-yn1bdPH78uPzc3t1fXy8VNYzkXU8MZdJyItkfRtc47SylRgmHPJXEKLCqlBMVeom870qESwnNUyJG3VkvJTqvrWbePuDYPKWww_TYRg_kTiGllME3BDs5IrgVo2jGmeCvQKw8dZY7TTvbohSpaH2ath223cb1145RweCb6_GYM380q7oyQIDXXReDtQSDFn1uXJ7MJeV8bHF3cZkOpkrz0gbECvfgPuo7bNJZSGVqyk4qAhIK6nFErLB8Io4_lXVtm7zbBxtH5UOILQQglupW0EGAm2BRzTs4_ZQ_E7C1gZguYYgGzt4AhhfPm328_Mf42nD0CRIKoJw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546780171</pqid></control><display><type>article</type><title>Overview: an iPS cell stock at CiRA</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Umekage, Masafumi ; Sato, Yoshiko ; Takasu, Naoko</creator><creatorcontrib>Umekage, Masafumi ; Sato, Yoshiko ; Takasu, Naoko</creatorcontrib><description>Induced pluripotent stem cells (iPSCs) can be produced from various somatic cells and have the ability to differentiate into various cells and tissues of the body. Regenerative medicine using iPSCs is expected to manage diseases lacking effective treatments at present. We are establishing a safe and effective iPSC stock that can be used for regenerative medicine. Our iPSC stock is recruited from healthy, consenting HLA-type homozygous donors and is made with peripheral blood-derived mononuclear cells or umbilical cord blood. We hope to minimize the influence of immune rejection by preparing HLA homozygous iPSCs. Our stock is made at the Cell Processing Center (CPC), Center for iPS Cell Research and Application (CiRA). We are preparing iPS cells that maximize matching of the Japanese population at the major HLA loci. This iPSC stock is intended to be offered not only to Japanese centers but also overseas medical institutions and companies. In August 2015, we began offering the iPSC stock for regenerative medicine and now offer 21 clones made from 5 donors.</description><identifier>ISSN: 1880-9693</identifier><identifier>ISSN: 1880-8190</identifier><identifier>EISSN: 1880-8190</identifier><identifier>DOI: 10.1186/s41232-019-0106-0</identifier><identifier>PMID: 31497180</identifier><language>eng</language><publisher>England: Springer</publisher><subject>Clinical-grade ; Collaboration ; Haplotypes ; HLA ; iPS cells ; Manufacturing ; Morphology ; Mutation ; Plasmids ; Regenerative medicine ; Review ; Stem cells ; Stock ; Stock offerings ; Stocks ; Transplants & implants ; Umbilical cord</subject><ispartof>Inflammation and Regeneration, 2019-09, Vol.39 (1), p.17-17, Article 17</ispartof><rights>COPYRIGHT 2019 Springer</rights><rights>2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</rights><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c556t-531b5064da6b4efec220863ad570e81ca88862ad7af4b0ba866f5a8a5a54c9773</citedby><cites>FETCH-LOGICAL-c556t-531b5064da6b4efec220863ad570e81ca88862ad7af4b0ba866f5a8a5a54c9773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717959/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717959/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31497180$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Umekage, Masafumi</creatorcontrib><creatorcontrib>Sato, Yoshiko</creatorcontrib><creatorcontrib>Takasu, Naoko</creatorcontrib><title>Overview: an iPS cell stock at CiRA</title><title>Inflammation and Regeneration</title><addtitle>Inflamm Regen</addtitle><description>Induced pluripotent stem cells (iPSCs) can be produced from various somatic cells and have the ability to differentiate into various cells and tissues of the body. Regenerative medicine using iPSCs is expected to manage diseases lacking effective treatments at present. We are establishing a safe and effective iPSC stock that can be used for regenerative medicine. Our iPSC stock is recruited from healthy, consenting HLA-type homozygous donors and is made with peripheral blood-derived mononuclear cells or umbilical cord blood. We hope to minimize the influence of immune rejection by preparing HLA homozygous iPSCs. Our stock is made at the Cell Processing Center (CPC), Center for iPS Cell Research and Application (CiRA). We are preparing iPS cells that maximize matching of the Japanese population at the major HLA loci. This iPSC stock is intended to be offered not only to Japanese centers but also overseas medical institutions and companies. In August 2015, we began offering the iPSC stock for regenerative medicine and now offer 21 clones made from 5 donors.</description><subject>Clinical-grade</subject><subject>Collaboration</subject><subject>Haplotypes</subject><subject>HLA</subject><subject>iPS cells</subject><subject>Manufacturing</subject><subject>Morphology</subject><subject>Mutation</subject><subject>Plasmids</subject><subject>Regenerative medicine</subject><subject>Review</subject><subject>Stem cells</subject><subject>Stock</subject><subject>Stock offerings</subject><subject>Stocks</subject><subject>Transplants & implants</subject><subject>Umbilical cord</subject><issn>1880-9693</issn><issn>1880-8190</issn><issn>1880-8190</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNpdUl1rFDEUHcRiS9sf4IsM9MWXqbnJ5MsHYVm0FgotVZ_DnUyyZp2d1GR2xX_frLMWa0JIuDnn5ObeU1WvgVwCKPEut0AZbQjosohoyIvqBJQijQJNXh7OWmh2XJ3nvCZlcME56FfVMYNWS1DkpLq43bm0C-7X-xrHOtx9qa0bhjpP0f6ocaqX4X5xVh15HLI7P-yn1bdPH78uPzc3t1fXy8VNYzkXU8MZdJyItkfRtc47SylRgmHPJXEKLCqlBMVeom870qESwnNUyJG3VkvJTqvrWbePuDYPKWww_TYRg_kTiGllME3BDs5IrgVo2jGmeCvQKw8dZY7TTvbohSpaH2ath223cb1145RweCb6_GYM380q7oyQIDXXReDtQSDFn1uXJ7MJeV8bHF3cZkOpkrz0gbECvfgPuo7bNJZSGVqyk4qAhIK6nFErLB8Io4_lXVtm7zbBxtH5UOILQQglupW0EGAm2BRzTs4_ZQ_E7C1gZguYYgGzt4AhhfPm328_Mf42nD0CRIKoJw</recordid><startdate>20190902</startdate><enddate>20190902</enddate><creator>Umekage, Masafumi</creator><creator>Sato, Yoshiko</creator><creator>Takasu, Naoko</creator><general>Springer</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190902</creationdate><title>Overview: an iPS cell stock at CiRA</title><author>Umekage, Masafumi ; Sato, Yoshiko ; Takasu, Naoko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c556t-531b5064da6b4efec220863ad570e81ca88862ad7af4b0ba866f5a8a5a54c9773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Clinical-grade</topic><topic>Collaboration</topic><topic>Haplotypes</topic><topic>HLA</topic><topic>iPS cells</topic><topic>Manufacturing</topic><topic>Morphology</topic><topic>Mutation</topic><topic>Plasmids</topic><topic>Regenerative medicine</topic><topic>Review</topic><topic>Stem cells</topic><topic>Stock</topic><topic>Stock offerings</topic><topic>Stocks</topic><topic>Transplants & implants</topic><topic>Umbilical cord</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Umekage, Masafumi</creatorcontrib><creatorcontrib>Sato, Yoshiko</creatorcontrib><creatorcontrib>Takasu, Naoko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Inflammation and Regeneration</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Umekage, Masafumi</au><au>Sato, Yoshiko</au><au>Takasu, Naoko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overview: an iPS cell stock at CiRA</atitle><jtitle>Inflammation and Regeneration</jtitle><addtitle>Inflamm Regen</addtitle><date>2019-09-02</date><risdate>2019</risdate><volume>39</volume><issue>1</issue><spage>17</spage><epage>17</epage><pages>17-17</pages><artnum>17</artnum><issn>1880-9693</issn><issn>1880-8190</issn><eissn>1880-8190</eissn><abstract>Induced pluripotent stem cells (iPSCs) can be produced from various somatic cells and have the ability to differentiate into various cells and tissues of the body. Regenerative medicine using iPSCs is expected to manage diseases lacking effective treatments at present. We are establishing a safe and effective iPSC stock that can be used for regenerative medicine. Our iPSC stock is recruited from healthy, consenting HLA-type homozygous donors and is made with peripheral blood-derived mononuclear cells or umbilical cord blood. We hope to minimize the influence of immune rejection by preparing HLA homozygous iPSCs. Our stock is made at the Cell Processing Center (CPC), Center for iPS Cell Research and Application (CiRA). We are preparing iPS cells that maximize matching of the Japanese population at the major HLA loci. This iPSC stock is intended to be offered not only to Japanese centers but also overseas medical institutions and companies. In August 2015, we began offering the iPSC stock for regenerative medicine and now offer 21 clones made from 5 donors.</abstract><cop>England</cop><pub>Springer</pub><pmid>31497180</pmid><doi>10.1186/s41232-019-0106-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1880-9693 |
| ispartof | Inflammation and Regeneration, 2019-09, Vol.39 (1), p.17-17, Article 17 |
| issn | 1880-9693 1880-8190 1880-8190 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6717959 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Springer Nature OA Free Journals; Springer Nature - Complete Springer Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Clinical-grade Collaboration Haplotypes HLA iPS cells Manufacturing Morphology Mutation Plasmids Regenerative medicine Review Stem cells Stock Stock offerings Stocks Transplants & implants Umbilical cord |
| title | Overview: an iPS cell stock at CiRA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A14%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overview:%20an%20iPS%20cell%20stock%20at%20CiRA&rft.jtitle=Inflammation%20and%20Regeneration&rft.au=Umekage,%20Masafumi&rft.date=2019-09-02&rft.volume=39&rft.issue=1&rft.spage=17&rft.epage=17&rft.pages=17-17&rft.artnum=17&rft.issn=1880-9693&rft.eissn=1880-8190&rft_id=info:doi/10.1186/s41232-019-0106-0&rft_dat=%3Cgale_doaj_%3EA600209472%3C/gale_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2546780171&rft_id=info:pmid/31497180&rft_galeid=A600209472&rft_doaj_id=oai_doaj_org_article_7596192b338546af8f1b23e52b7daf68&rfr_iscdi=true |